Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

HP, Levi Strauss, Roblox Rise Premarket; JD.com, Wayfair Drop

Published 07/04/2022, 13:14
Updated 07/04/2022, 13:14
© Reuters

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Thursday, April 7th. Please refresh for updates.

  • Levi Strauss (NYSE:LEVI) stock rose 2% after the denim retailer reported better than expected first-quarter earnings, selling more of its higher priced jeans and T-shirts.

  • HP (NYSE:HPQ) stock soared over 12% after Warren Buffett’s Berkshire Hathaway (NYSE:BRKa), up 0.2%, disclosed it had bought a $4.2 billion stake in the information technology company.

  • Meta Platforms (NASDAQ:FB) stock rose 0.7% following reports the owner of Facebook is working on a plan to introduce virtual coins, tokens and lending services to its apps.

  • Euronav (NYSE:EURN) stock rose 10% after the Belgian oil tanker group announced plans to merge with smaller Oslo-listed rival Frontline (NYSE:FRO), down 5.3%, in an all-stock transaction valued at $4.2 billion, a move aimed at cutting costs.

  • Ford (NYSE:F) stock fell 1.2% after Barclays downgraded its stance on the auto giant to ‘equal weight’ from ‘overweight’, saying the company will struggle as chip shortages continue.

  • JD.com (NASDAQ:JD) ADRs fell 1.4% after the billionaire founder of the Chinese e-commerce giant, Richard Liu, stepped down from the CEO role as Beijing continues to tighten regulation on its domestic technology sector.

  • Roblox (NYSE:RBLX) stock rose 2% after Citigroup started coverage of the online game creator with a ‘buy’ rating, saying it’s now trading at an attractive price after a rough start to the year.

  • Wayfair (NYSE:W) stock fell 3.4% after Wells Fargo downgraded its stance to ‘underweight’ from ‘equal weight’, saying inflation and uncertainty in the housing market will hurt the online furniture retailer.

  • Pfizer (NYSE:PFE) stock rose 0.2% after the drugmaker announced plans to buy privately-held ReViral for as much as $525 million, to gain access to some experimental drugs.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.